According to a recent LinkedIn post from C Ray Therapeutics, the company plans to participate in the SNMMI Annual Meeting in Los Angeles from May 30 to June 2, 2026, with a presence at Booth #2323. The post emphasizes the team’s interest in substantive discussions that extend beyond standard conference booth interactions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights several themes it views as important for the radiopharmaceutical and theranostics sector, including the maturing pipeline for Cu-64, Ac-225, and Pb-212 programs. It also points to supply chain resilience and the development of durable, cross-border partnerships, including those involving China, as key operational and strategic questions for developers.
For investors, the post suggests that C Ray Therapeutics is positioning itself within evolving radiopharmaceutical value chains, where isotope availability, manufacturing reliability, and international collaboration may become differentiators. Active engagement at SNMMI 2026 could help the company build or strengthen commercial, development, and CDMO-style relationships that may influence future revenue visibility and competitive standing.
The reference to CRDMO and RDC in the post indicates an interest in contract development and manufacturing-type roles in radiopharmaceuticals, potentially aligning C Ray Therapeutics with outsourced development and production trends in nuclear medicine. If the company can secure partnerships or supply agreements around Cu-64, Ac-225, and Pb-212 programs, it could gain exposure to growth in theranostics and nuclear medicine markets, though the post does not disclose any specific deals or financial details.